ProShare Advisors
STLN

ProShare Advisors’s Starling Oncology STLN Stock Holding History

ProShare Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.4K Sell
10,026
-1,535
-13% -$6.45K ﹤0.01% 1835
2026
Q1 		$35.5K Sell
11,561
-908
-7% -$2.78K ﹤0.01% 1810
2025
Q4 		$44.4K Buy
12,469
+2,208
+22% +$8.19K ﹤0.01% 1969
2025
Q3 		$35.8K Sell
10,261
-1,843
-15% -$6.32K ﹤0.01% 1960
2025
Q2 		$24.8K Buy
+12,104
New +$30.3K ﹤0.01% 2055

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ProShare Advisors's STLN Position: Q2 2026 in Review

ProShare Advisors reduced its Starling Oncology (STLN) stake by 13% in Q2 2026, selling an estimated $6.45K and leaving 10,026 shares worth $54.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1835.

ProShare Advisors first reported a position in STLN in Q2 2025 and has held it in 5 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • ProShare Advisors held 10,026 shares of Starling Oncology worth $54.4K as of Q2 2026.
  • ProShare Advisors sold 1,535 Starling Oncology shares in Q2 2026, an estimated $6.45K.
  • Starling Oncology made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1835 holding.
  • ProShare Advisors first reported a position in Starling Oncology in Q2 2025 and has held it in 5 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.